4D Molecular announces positive interim 1.5-3.5 year data for 4D-150 in wet AMD; 79-92% injection reduction

4D Molecular Therapeutics, Inc.

Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.
Phase 2b recently diagnosed subgroup (Phase 3 comparable): 92% reduction in mean supplemental injections vs aflibercept at 1.5 years.
Phase 2b broad cohort: 82% reduction; Phase 1/2a severe recalcitrant: 79% reduction at 2 years.
Safety: 2.8% (2/71) mild transient IOI within 28 weeks; no new IOI after 28 weeks; no hypotony, endophthalmitis, vasculitis.
Consistent dose response favoring Phase 3 dose (3E10 vg/eye) over lower dose across all cohorts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.